You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
譽衡藥業(002437.SZ)擬14.2億元出售澳諾製藥100%股權予華潤三九
格隆匯 11-27 18:41

格隆匯11月27日丨譽衡藥業(002437.SZ)公佈,公司擬與華潤三九醫藥股份有限公司(“華潤三九”)簽署《關於澳諾(中國)製藥有限公司之股權轉讓合同》,公司擬將持有的澳諾(中國)製藥有限公司(“澳諾製藥”、“交易標的”、“目標公司”)100%股權以人民幣14.20億元交易價格出售給華潤三九。

截止20199月底,公司資產負債率為51.23%,處於行業偏高水平。此次交易所獲資金優先償還公司債務,降低資產負債率財務費用,改善債務結構,確保公司現金流充裕,應對經營業績壓力,推動公司持續穩定的發展。

若此次交易得以順利實施,所獲資金也可助力公司與戰略投資人共同聚焦生物藥戰略領域的快速推進

交易對方以現金方式支付此次交易對價,如此次交易順利實施,將有利於改善公司運營資金及現金流狀況,緩解公司短期債務壓力,有效降低公司財務風險,同時,也可為公司後續生物藥研發等戰略轉型提供一定的資金支持,此次交易符合公司實際經營情況及未來發展需要。

若此次交易順利實施,在不考慮相關税費和交易成本的情況下,此次交在公司母公司層面產生投資收益約為10億元(最終數據以經會計師事務所出具的審計報告為準)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account